Important European patent approval for Episurf Medical within 3D visualisation
The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method of generating a three dimensional representation of a joint”, covers a medical image segmentation process for 3D visualisation of anatomical joints. Image segmentation is a part of the technology around Episurf Medical’s individualised joint implants and surgical instruments.
"This is a comprehensive patent for protection in the field of 3D visualisation of joints. The image-based segmentation forms the basis for all Episurf Medical’s products, and this is a very exciting and rapidly growing field. This announcement from the EPO is thus great news for us. The patent complements Episurf Medical's patents within medical imaging with a broader protection”, comments Katarina Flodström, COO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CET on 6 March 2020.
Tags: